RBC Capital initiated coverage of Sandoz with an Outperform rating and CHF 33 price target. s a stand-alone leading generics company, Sandoz should benefit from the “huge” emerging biosimilars opportunity, particularly in the US., the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SDZNY: